15 Skyline Drive
About Acorda TherapeuticsAcorda Therapeutics is a privately held biotechnology company developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS.
Fampridine-SR acts to combat the effects of demyelination in the spinal cord. Myelin is the insulating sheath around nerve processes; when it is damaged due to trauma or disease, electrical impulses from the brain cannot be conducted past the demyelinated area. Fampridine-SR chemically blocks the exposed voltage-gated potassium channels, allowing the impulse from the brain to be conducted more normally past the area of damage. Fampridine is being studied in Phase 3 clinical trials to evaluate its efficacy in reducing spasticity in people with chronic spinal cord injury. Secondary endpoints in the study include evaluating its effect on bladder, bowel, and sexual function. The Company is also conducting a 152 patient, late Phase 2 clinical study in MS to evaluate Fampridine-SR's efficacy in walking speed and muscle strength.
Acorda's technology platform also includes two remyelinating agents in preclinical development for MS. The first is M1, a class of human monoclonal antibodies that have been shown to remyelinate the central nervous system in animal models, and the second is GGF2, a product of the neuregulin 1 gene. Preclinical studies have shown that GGF2 can stimulate the cell growth necessary to protect and regenerate damaged myelin. Additionally, Acorda is developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord and brain.
In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.
Ron Cohen, M.D., President and CEO Andrew R. Blight, Ph.D., Executive Vice President, Research & Development Mary Fisher, Vice President, Marketing and Strategic Planning Elliott A. Gruskin, Ph.D., Vice President, Research & Development Mitchell Katz, Ph.D., Vice President, Clinical Programs David Lawrence, Vice President, Finance Mark R. E. Pinney, C.F.A., Chief Financial Officer and Director Harold Safferstein, Ph.D., J.D., Vice President, Business Development
Last Updated: 05-09-03
508 articles with Acorda Therapeutics
Acorda Therapeutics, Inc. provided financial and pipeline updates for the fourth quarter and full year ended December 31, 2018.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Peter S. Carbone has joined the Company as Senior Vice President, Quality.
Acorda Therapeutics, Inc. will host a conference call and webcast in conjunction with its fourth quarter/year end 2018 update and financial results on Thursday, February 14 at 4:30 p.m. ET.
Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA™ (levodopa inhalation powder)
SPAN℠-PD, the efficacy and safety study of INBRIJA (CVT-301), showed significant improvement in motor function during OFF periods in people with Parkinson’s on a carbidopa/levodopa regimen
In a reflection on the annual healthcare conference, VC Bruce Booth criticizes the high cost of attending JPM, as well as the focus on market share instead of patients.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided 2018 highlights, 2019 guidance and commercialization plans for INBRIJA at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco.
With the holidays upon us, along with the end of 2018 and the beginning of 2019, the FDA squeezed some target action dates into the last weeks and beginning of the new year. As it turned out, these appear to be a mixed bag of extensions, resubmissions and supplemental applications, some of which ...
After a delay in review, the FDA approved Acorda's Inbrija for the intermittent treatment of OFF episodes of Parkinson's.
First and Only FDA-Approved Inhaled Levodopa for Intermittent Treatment of OFF Episodes in People with Parkinson’s Taking Carbidopa/Levodopa
Acorda's President and CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9 at 8:00am PST / 5:00am EST.
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today launched Framing OFF Through Art℠, a new initiative that uses the power of art to allow people with Parkinson’s to help recognize and articulate their OFF period experiences.
Two weeks after acquiring two drugs from AstraZeneca in a $700 million deal, Germany-based Grünenthal flexed its M&A muscle again to acquire Averitas Pharma to extend its commercial footprint in the United States.
Acorda Therapeutics, Inc. announced that Acorda's President and CEO will present at the Stifel 2018 Healthcare Conference.
AMPYRA® (dalfampridine) Q3 2018 net revenue of $138 million; 2018 net revenue guidance increased from $330-$350 million to more than $400 million
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Acorda Therapeutics, Inc. will host a conference call and webcast to report its third quarter 2018 update and financial results on Wednesday, October 31 at 8:30 a.m. ET.
Acorda to Present Data for INBRIJA™ (levodopa inhalation powder) at International Congress of Parkinson’s Disease and Movement Disorders
INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.
It looks to be a pretty busy week for the U.S. Food and Drug Administration (FDA), with a number of target action dates for various drugs. Some were delayed, and some were already approved, but there are still a number on the schedule. Here’s a look.
Acorda Therapeutics’ week started off badly and has only gotten worse. It started off with the loss of an appeal for some of its Ampyra patents and has ended with the U.S. FDA's decision to delay a ruling for its Parkinson’s disease treatment.
New PDUFA Date of January 5, 2019